1979 Bacillary Congress?

The 1979 Bacillary Congress was held in Geneva from 14 to 21 September, convened by the Geneva Sanitary Bureau to evaluate and standardize treatment outcomes across the expanding field of serum therapy. It marked the formal institutional acceptance of the Halloway-Umezaki method as the primary systemic alternative to the azo drugs, and established protocols for measuring and comparing serum efficacy across national systems that had developed independently since the Bacillary Congress of Geneva in 1952.

The immediate occasion was the five-year accumulation of clinical data from serum therapy trials conducted at the Infectious Disease Research Centre in Cambridge, the Pasteur Institute, and specialized facilities in North America and Japan. The Cambridge team, led by researchers who had collaborated with Dorothy Umezaki during the development phase, presented survival analysis data using the Kaplan-Meier method on three major bacterial conditions: endocarditis, meningitis, and wound sepsis following trauma. The results showed consistent serum efficacy — defined as either recovery without reinfection or survival beyond twelve months — ranging from 42 percent in acute endocarditis to 68 percent in meningitis when serum therapy was administered within forty-eight hours of bacteraemia confirmation. These figures, modest by earlier hopes, were sufficient to establish serum therapy as the only available systemic treatment capable of intervening once asepsis maximalism had failed to prevent infection.

The Congress formally adopted the International Serum Registry, a coordinated database established in 1975 to track donor serum batches, patient outcomes, and adverse reactions across participating nations. By 1979, the registry held records for more than eighteen thousand serum therapy cases, supplied by facilities in twelve countries. The registry served two purposes: it provided the statistical foundation for refining treatment protocols, and it created a permanent record of resource allocation, allowing national health bureaucracies to forecast serum production requirements based on infection incidence and patient age. The Congress standardized reporting timelines — clinical follow-up at three months, six months, and one year — and established that any serum therapy outcome could be included in the registry only if the causative bacterium had been cultured and identified before treatment began.

A secondary but consequential decision concerned specialized serum farms. By 1979, the production of hyperimmunized animal serum — primarily from horses, but also from sheep and rabbits depending on the target pathogen — had become a specialized agricultural and biotechnical sector. The Congress established minimum standards for animal welfare, serum collection frequency, and batch testing for contamination, bringing a previously unregulated industry under coordinated international oversight. The directive specified that serum farms must maintain detailed records of each animal's immunization history and antibody titre, and that no serum batch could enter clinical use until tested for both target antibody concentration and the absence of contaminating organisms. Several Eastern European and Soviet facilities were brought into the registry system for the first time, substantially expanding available serum stocks but also creating the technical problem of standardizing quality across systems that had developed in isolation.

The Congress also formalized a subordinate category of treatment protocols for conditions too rare or too rapidly fatal to accumulate systematic data. Diphtheria antitoxin, already in use since the 1890s, was grandfathered into the system; the Congress affirmed that its efficacy would no longer be subjected to clinical trial, as four generations of use without significant harm and visible clinical benefit established it as a baseline treatment. Similar exemptions were discussed for plague serum and meningococcal antitoxin, though consensus on the latter was incomplete. Some delegates, particularly from the Institute for the History of Bacteriology in Berlin, argued that the absence of systematic trial data for meningococcal serum represented a failure of documentation rather than a reason to exempt the treatment. The Congress ultimately required that all antitoxins enter the registry prospectively, even those already in use.

The proceedings were published by the Geneva Sanitary Bureau in 1980 and remain the foundational coordinating document for serum therapy standardization. The statistical methods adopted at the Congress, particularly the decision to use three-tiered follow-up and the Kaplan-Meier estimator for survival analysis, shaped the design of all subsequent infection trials and influenced the broader development of medical statistics in the absence of rapid chemical cure. By establishing that serum therapy outcomes could be quantified, compared, and improved through systematic observation, the Congress transformed serum therapy from a collection of national experiments into a single coordinated international system of treatment and measurement.